{"adverse_reactions":["ADVERSE REACTIONS Flushing, sweating, sharply lowered blood pressure, hypothermia, stupor, and ultimately respiratory depression."],"contraindications":["CONTRAINDICATIONS Magnesium Chloride Injection should not be administered if there is renal impairment, marked myocardial disease or to comatose patients."],"description":["DESCRIPTION Magnesium Chloride Injection is a sterile solution of Magnesium Chloride Hexahydrate in Water for Injection q.s. Each mL contains: Magnesium Chloride Hexahydrate 200 mg, Sodium Chloride 9 mg, Benzyl Alcohol 1% as a preservative, Water for Injection, q.s. pH adjusted with Hydrochloric Acid and/or Sodium Hydroxide. Total osmolarity equivalent to 2951 mOsmol/L . Contains 1.97 mEq of Mg ++ and Cl - per mL. The structural formula is MgCl 2 •6H 2 O"],"dosage_and_administration":["DOSAGE AND ADMINISTRATION For intravenous infusion: 4 grams in 250 mL of 5% Dextrose Injection, at a rate not exceeding 3 mL per minute. Serum magnesium levels should serve as a guide to continued dosage."],"effective_time":"20110225","how_supplied":["HOW SUPPLIED: Magnesium Chloride Injection 200 mg/mL (20% w/v) NDC 66860-040-01 50 mL Multiple Dose Vial Individually boxed. Store at controlled room temperature 15°–30°C (59°–86°F)."],"id":"074cb3cc-e130-4e11-9397-625fe2f3d353","indications_and_usage":["INDICATIONS As an electrolyte replenisher in magnesium deficiencies."],"openfda":{},"package_label_principal_display_panel":["Vial Label NDC 66860-040-01 CURA Pharmaceutical Co., Inc. MAGNESIUM CHLORIDE INJECTION 200 mg/mL (20% w/v) 2.951 mOsmol/mL 50 mL MULTIPLE DOSE VIAL Rx ONLY 50 mL MULTIPLE DOSE VIAL"],"precautions":["PRECAUTIONS The usual precautions for parenteral administration should be observed. Administer with caution if flushing and sweating occurs. A preparation of a calcium salt should be readily available for intravenous injection to counteract potential serious signs of magnesium intoxication. As long as deep tendon reflexes are active it is probable that the patient will not develop respiratory paralysis. Respiration and blood pressure should be carefully observed during and after administration of Magnesium Chloride Injection. Pregnancy: Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with magnesium chloride. It is also not known whether magnesium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium chloride should be given to a pregnant woman only if clearly needed."],"pregnancy":["Pregnancy: Teratogenic Effects: Pregnancy Category C. Animal reproduction studies have not been conducted with magnesium chloride. It is also not known whether magnesium chloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Magnesium chloride should be given to a pregnant woman only if clearly needed."],"set_id":"074cb3cc-e130-4e11-9397-625fe2f3d353","spl_product_data_elements":["Magnesium Chloride Magnesium Chloride Magnesium Chloride MAGNESIUM CATION sodium chloride benzyl alcohol hydrochloric acid sodium hydroxide"],"spl_unclassified_section":["200 mg/mL (20% w/v) 2.951 mOsmol/mL Rx Only","ACTIONS Magnesium is the second most plentiful cation within cellular fluids. It is an important activator of many enzyme systems, and deficits are accompanied by a variety of functional disturbances.","USUAL DOSAGE RANGE: 1 to 40 grams daily. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.","Manufactured by: Claris Lifesciences Limited Ahmedabad, Gujarat-382 213, INDIA For: CURA Pharmaceutical Co., Inc. Eatontown, NJ 07724, USA Issue Date:11/2004 IEE/C/4/Magnesium Chloride/00/4"],"version":"1","warnings":["WARNINGS Do not use if a precipitate is present. This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration."]}